- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00499824
GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets (GIANT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Description of intervention(s) / exposure and control treatment: This is a prospective multinational, multicentre, cluster-randomised study conducted within the primary care setting, with two parallel treatment arms: standard clinical practice versus education on diabetes management using International Diabetes Federation - Western Pacific Region (IDF-WPR) "Type 2 diabetes practical targets and treatments". The study duration will be 12 months.
100 General Practitioners (GPs) (10 per country) will be randomised to receive education on the IDF-WPR guidelines or to receive no trial-related education.
- GPs in both groups will be required to recruit 4 of their own patients meeting the eligibility criteria. The complete entry criteria are detailed in a following section.
- GPs in both groups will manage the recruited patients according to their own clinical judgement. Frequency of patient visits to the GP's clinic will be determined by the GP. All medication prescribed by the GPs should already be registered in the participating countries.
- Blood sampling of patients will be required at Study Visit 1 (Screening/Baseline), Study Visit 2 (month 6) and Study Visit 3 (month 12).
The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). The educational program for the GPs randomised to the intervention arm will:
- Combine didactic and interactive sessions.
- Involve opinion leaders, i.e. the national lead investigator
- Aim to resolve barriers to practical implementation of guidelines already identified from previous studies (e.g. discuss starting insulin)
- Present the evidence for the guidelines.
- Highlight any conflicts between the guidelines and local prescribing regulations, and confirm the need to follow the local prescribing regulations in these instances
- Involve an initial educational symposium and a follow-up continuing medical education symposium at 3 months
Organisational changes to improve guideline adherence for the study will include:
- Paper or electronic reminders of the guidelines will be sent to GPs every 3 months.
- Desktop reminders cards with key guideline algorithms.
- Insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse (at the time of review of the practitioner's baseline HbA1c utilisation).
Patient-centred approaches to improve guideline adherence for the study will include:
- Encouragement and empowerment of patients to ask questions of the treating practitioners
- Provision of each patient with a "diabetes passport" to be held by the patient, to encourage discussion between the patient and practitioner and also recording of results of medical examinations. This will be provided at the baseline visit to the national coordinating centre.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100044
- Department of Endocrinology & Metabolism, Peking University People's Hospital
-
-
Hong Kong
-
Shatin, Hong Kong, China
- Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
-
-
-
-
-
Surabaya, Indonesia, 60286
- Diabetes and Nutrition Center, Dr. Soetomo Teaching Hospital - Airlangga University,
-
-
-
-
-
Seoul, Korea, Republic of
- Department of Endocrinology & Metabolism, Kangnam St. Mary's Hospital, The Catholic University of Medicine
-
-
-
-
-
Johor Bahru, Malaysia, 80100
- School of Medicine and Health Sciences, Monash University House
-
-
-
-
-
Manila, Philippines
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of the Philippines College of Medicine
-
-
-
-
-
Singapore, Singapore, 258499
- Diabetes, Lipid and Endocrine Practice, Gleneagles Medical Centre
-
-
-
-
-
Taipei, Taiwan
- Dept of Medical Research and Education, Taipei Veterans General Hospital,
-
-
-
-
-
Bangkok, Thailand, 10400
- Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital,
-
-
-
-
Dongda district
-
Hanoi, Dongda district, Vietnam
- National Hospital of Endocrinology,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Men or women who are 30 to 75 years of age (inclusive) at Study Visit 1.
- Clinical diagnosis of type 2 diabetes (defined according to IDF Guidelines) for a minimum of 6 months prior to Study Visit 1
- Patients for whom the GP is the primary medical provider of diabetes care and for whom referral to another doctor for diabetes care is not anticipated within 3 months of Study Visit 1
- Patients who give informed consent to participate.
EXCLUSION CRITERIA
- Patients with type 1 diabetes mellitus
- Patients with any previous episode of ketoacidosis
- Patients who required chronic use (>/= 6 months) of insulin at any time in the past, with the exception of females during pregnancy
- Patients receiving insulin treatment at Study Visit 1 or within the previous 6 months, with the exception of patients who received short-term treatment (= 7 days) with insulin to maintain glycaemic control for an acute event (e.g. hospitalisation or medical procedure/intervention, infection or trauma).
- Treatment with glucocorticoid at Study Visit 1 or within the previous 6 months, with the exception of topical or inhaled glucocorticoid
- Females who are pregnant or considering pregnancy or stopping contraception within the course of the study
- Patients with end-stage renal disease, defined as glomerular filtration rate (GFR) by the MDRD (Modification of Diet in Renal Disease) formula < 15 ml/min/1.73 m2, or on renal replacement therapy with haemodialysis, peritoneal dialysis or renal transplant.
- Patients with psychiatric disease, active drug or alcohol abuse or other cognitive impairment that may interfere with treatment compliance.
- Receipt of any investigational drug within 30 days of Study Visit 1.
- Patients receiving diabetes care from another doctor (specialist endocrinologist, general physician, or another GP) Other eligibility criteria considerations The HbA1c at entry for newly recruited patients will be monitored centrally. If there is a significant risk that more than 25% of the total study population will have a baseline HbA1c </= 6.5%, then recruitment of subsequent patients will be restricted to those with HbA1c > 6.5%.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
|
The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve: an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a "diabetes passport" to be held by the patient. |
No Intervention: 2
Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice
Time Frame: 6 & 12 months
|
6 & 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jonathan E Shaw, MD MRCP FRACP, International Diabetes Institute, Australia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDI Project 4/2006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Education of general practitioners on the IDF-WPR guidelines
-
Medical Corps, Israel Defense ForceWithdrawnSmoking Cessation | Weight Reduction | Physical Fitness Habits | Balanced Nutrition | Reduction of StressIsrael
-
Yangzhou UniversityCompletedType 2 Diabetes Mellitus | Health Education | Self-Management | Fear of Hypoglycemia | Impaired Awareness of HypoglycemiaChina
-
Instituto de Cardiologia do Rio Grande do SulCompleted
-
Loma Linda UniversityCompleted
-
University Hospital, ToulouseRecruitingBacterial InfectionsFrance
-
Trakya UniversityCompletedQuality of Life | Rheumatoid Arthritis | Depression, Anxiety | Nurse's RoleTurkey
-
Sengkang General HospitalUniversiti Putra Malaysia; University of Malaya; Khoo Teck Puat Hospital; Singapore... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes Complications | FastingSingapore
-
Philip Morris Products S.A.Terminated
-
University of MinhoCompletedSleep | Child | Pediatric Obesity | Dietary Habits | Executive Function | Child Health | Family HealthPortugal
-
Philip Morris Products S.A.Terminated